Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | TSPO | P30536 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 7/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4630041 | 0.85 | GRM5 (0.75) | GRM5KCNH2 | |
| SCHEMBL4630177 | 0.84 | GRM5 (1.00) | GRM5KCNH2 | |
| SCHEMBL4629672 | 0.81 | GRM5 (1.00) | GRM5 | |
| SCHEMBL4630585 | 0.80 | GRM5 (0.78) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL4630732 | 0.78 | GRM5 (0.78) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL4631050 | 0.78 | GRM5 (0.74) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL4630148 | 0.78 | GRM5 (1.00) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL4630257 | 0.78 | GRM5 (0.82) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL4630909 | 0.77 | GRM5 (0.81) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL4630692 | 0.77 | GRM5 (0.77) | GRM5KCNH2ADRB3TSPOTMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229917-A1 | Imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-18 | — | — | US | claimed |
| EP-1606277-B8 | IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-10-15 | — | — | EP | disclosed |
| EP-1606277-B1 | IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-05-14 | — | — | EP | disclosed |
| US-7153874-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1606277-A1 | IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-21 | — | — | EP | disclosed |
| US-20040229917-A1 | Imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-18 | — | — | US | disclosed |
| WO-2004080998-A1 | IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229917-A1 | Imidazole derivatives | GRIK4, GRIA4, GRIK5 | GRM5 10/4885KCNH2 393/4885ADRB3 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.